Drugs / Dingkun Dan
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03264638 | Oct 2016 → Aug 2018 | polycystic ovary syndrome | Aijun Sun | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07376824 | Dec 2024 → Dec 2026 expected | ovarian dysfunction | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 42 trials · 1 missed | ||||||
| Phase 4 | NCT07580950 | Oct 2025 → Jun 2028 expected | functional hypothalamic amenorrhea | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT03953716 | Jun 2019 → Jun 2020 | primary dysmenorrhea | Peking Union Medical College Hospital | Unknown | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dingkundan | “Dingkun Dan 7g, twice daily (bid) for 21 days per month, administered orally for 3 treatment cycles.” NCT07376824 ↗3“traditional Chinese medicine(Ba Zhen Yi Mu Pill and Dingkun Dan）” NCT07580950 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Dingkundan consists of multiple chinese herbs” NCT03264638 ↗ |
| Route | Oral | “Dingkundan 7g capsule by mouth” NCT03264638 ↗ |